坏死性小肠结肠炎的当前治疗选择：实际情况与挑战
Current therapy option for necrotizing enterocolitis: Practicalities and challenge.
作者信息
Wu Huihuan, Guo Kehang, Zhuo Zewei, Zeng Ruijie, Luo Yujun, Yang Qi, Li Jingwei, Jiang Rui, Huang Zena, Sha Weihong, Chen Hao
机构信息
Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
School of Medicine, South China University of Technology, Guangzhou, China.
出版信息
Front Pediatr. 2022 Jul 28;10:954735. doi: 10.3389/fped.2022.954735. eCollection 2022.
Necrotizing enterocolitis (NEC) is one of the most prevalent neonatal gastrointestinal disorders. Despite ongoing breakthroughs in its treatment and prevention, the incidence and mortality associated with NEC remain high. New therapeutic approaches, such as breast milk composition administration, stem cell therapy, immunotherapy, and fecal microbiota transplantation (FMT) have recently evolved the prevention and the treatment of NEC. This study investigated the most recent advances in NEC therapeutic approaches and discussed their applicability to bring new insight to NEC treatment.
坏死性小肠结肠炎（NEC）是最常见的新生儿胃肠道疾病之一。尽管在其治疗和预防方面不断取得突破，但与NEC相关的发病率和死亡率仍然很高。新的治疗方法，如母乳成分给药、干细胞疗法、免疫疗法和粪便微生物群移植（FMT），最近在NEC的预防和治疗方面取得了进展。本研究调查了NEC治疗方法的最新进展，并讨论了它们在为NEC治疗带来新见解方面的适用性。
Zotero 插件